Infos zu Corona - Aktuelle Informationen zu SARS-CoV-2 : 7a allg. zu Impfungen/ vaccinations

7a allg. zu Impfungen/ vaccinations » TZellfunktionen

Letzte Änderung: 27.10.2024 um 15:38 Uhr

Bei Personen mit B-Zell-Defizienz kann es sein, dass diese nach der Impfung zwar mangels B-Zellen nur wenige Antikörper bilden, die für einen erfolgreichen Immunschutz nicht ausreichend sind, aber eine gewisse T-Zell-Immunität aufbauen könnten. Hier hängt es wohl von der verbliebenen Restanzahl an B-Zellen und auch der Zahl von T-Zellen ab, ob hier eine ausreichende Schutzwirkung erzielt werden kann.

Weiterführende Links zum Artikel

★ Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases (Hinzugefügt: 29.12.2021 um 17:51 Uhr)
https://onlinelibrary.wiley.com/doi/abs/10.1002/art.42058
★ Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination (Hinzugefügt: 12.10.2021 um 11:04 Uhr)
https://www.science.org/doi/10.1126/science.abh1823
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome. (Hinzugefügt: 27.10.2024 um 15:38 Uhr)
https://www.biorxiv.org/content/10.1101/2024.10.23.619918v1
T-Cell Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Measured by an Interferon-γ Release Assay Is Strongly Associated With Patient Outcomes in Vaccinated Persons Hospitalized With Delta or Omicron Variants (Hinzugefügt: 05.08.2023 um 15:35 Uhr)
https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad260/7221140
Dysregulation of brain and choroid plexus cell types in severe COVID-19 (Hinzugefügt: 05.08.2023 um 11:38 Uhr)
https://www.nature.com/articles/s41586-021-03710-0
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T-cell recognition epitopes (Hinzugefügt: 20.12.2022 um 13:04 Uhr)
https://www.biorxiv.org/content/10.1101/2022.12.15.520569v1
Single-cell multiomics revealed the dynamics of antigen presentation, immune response and T cell activation in the COVID-19 positive and recovered individuals (Hinzugefügt: 06.12.2022 um 16:03 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2022.1034159/full?utm_source=S-TWT&utm_medium=SNET&utm_campaign=ECO_FIMMU_XXXXXXXX_auto-dlvrit
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2 (Hinzugefügt: 24.06.2022 um 09:42 Uhr)
https://www.science.org/doi/10.1126/sciimmunol.abl4509
T cells protect against COVID-19 in absence of antibody response (Hinzugefügt: 24.06.2022 um 09:16 Uhr)
https://www.nih.gov/news-events/nih-research-matters/t-cells-protect-against-covid-19-absence-antibody-response
Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR (Hinzugefügt: 24.06.2022 um 09:07 Uhr)
https://www.nature.com/articles/s41587-022-01347-6
Limited induction of lung-resident memory T cell responses against SARS-CoV-2 by mRNA vaccination (Hinzugefügt: 30.05.2022 um 14:17 Uhr)
https://www.medrxiv.org/content/10.1101/2022.05.25.22275300v1
Humoral and cellular immune memory to four COVID-19 vaccines (Hinzugefügt: 30.05.2022 um 13:53 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(22)00653-5
Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants (Hinzugefügt: 27.05.2022 um 08:21 Uhr)
https://www.pnas.org/doi/10.1073/pnas.2118312119
An efficient immunoassay for the B cell help function of SARS-CoV-2-specific memory CD4+ T cells (Hinzugefügt: 27.05.2022 um 08:18 Uhr)
https://www.cell.com/cell-reports-methods/fulltext/S2667-2375(22)00087-X
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? (Hinzugefügt: 10.05.2022 um 08:29 Uhr)
https://www.nature.com/articles/s41577-022-00716-1
TNFα-producing CD4+ T cells dominate the SARS-CoV-2-specific T cell response in COVID-19 outpatients and are associated with durable antibodies (Hinzugefügt: 10.05.2022 um 08:21 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(22)00165-3
SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals (Hinzugefügt: 30.04.2022 um 10:57 Uhr)
https://www.nature.com/articles/s41564-022-01106-y
SARS-CoV-2 evolution and immune escape in immunocompromised patients treated with exogenous antibodies (Hinzugefügt: 26.04.2022 um 13:42 Uhr)
https://www.medrxiv.org/content/10.1101/2022.04.12.22273675v1
SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells (Hinzugefügt: 08.04.2022 um 17:05 Uhr)
https://www.nature.com/articles/s41590-022-01184-4
Understanding T-cell responses to COVID-19 is essential for informing public health strategies (Hinzugefügt: 03.04.2022 um 17:03 Uhr)
https://www.science.org/doi/10.1126/sciimmunol.abo1303
Superantigens and SARS-CoV-2 (Hinzugefügt: 27.03.2022 um 07:57 Uhr)
https://www.mdpi.com/2076-0817/11/4/390/htm
SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity (Hinzugefügt: 16.03.2022 um 13:51 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2022.840126/full
KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19 (Hinzugefügt: 11.03.2022 um 11:18 Uhr)
https://www.science.org/doi/10.1126/science.abi9591
Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues (Hinzugefügt: 11.03.2022 um 10:42 Uhr)
https://www.science.org/doi/10.1126/sciimmunol.abo0535
Multiscale PHATE identifies multimodal signatures of COVID-19 (Hinzugefügt: 06.03.2022 um 18:56 Uhr)
https://www.nature.com/articles/s41587-021-01186-x
T-cell exhaustion may limit long-term immunity in COVID-19 patients (Hinzugefügt: 20.02.2022 um 13:21 Uhr)
https://www.drugtargetreview.com/news/81320/t-cell-exhaustion-may-limit-long-term-immunity-in-covid-19-patients/
The polarity and specificity of SARS-CoV2-specific T lymphocyte responses determine disease susceptibility (Hinzugefügt: 20.02.2022 um 12:24 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.18.21258477v1
T cell responses to SARS-CoV-2 spike cross-recognize Omicron (Hinzugefügt: 17.02.2022 um 06:22 Uhr)
https://www.nature.com/articles/s41586-022-04460-3
Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly (Hinzugefügt: 14.02.2022 um 16:30 Uhr)
https://www.jimmunol.org/content/early/2022/02/04/jimmunol.2100990
Zelluläre Immunantwort: Was nach dem Verschwinden der SARS-CoV-2-Antikörper übrig bleibt (Hinzugefügt: 14.02.2022 um 16:29 Uhr)
https://www.aerzteblatt.de/nachrichten/131603/Zellulaere-Immunantwort-Was-nach-dem-Verschwinden-der-SARS-CoV-2-Antikoerper-uebrig-bleibt
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant (Hinzugefügt: 24.01.2022 um 20:09 Uhr)
https://www.nature.com/articles/s41591-022-01700-x
Complement activation induces excessive T cell cytotoxicity in severe COVID-19 (Hinzugefügt: 22.01.2022 um 13:23 Uhr)
https://www.sciencedirect.com/science/article/pii/S0092867421015622
T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis (Hinzugefügt: 22.01.2022 um 12:52 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2020.589380/full
Kreuzreaktive T-Zellen tragen zum Schutz vor COVID-19-Infektion bei (Hinzugefügt: 13.01.2022 um 11:08 Uhr)
https://www.aerzteblatt.de/nachrichten/130837/Kreuzreaktive-T-Zellen-tragen-zum-Schutz-vor-COVID-19-Infektion-bei
BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype (Hinzugefügt: 11.01.2022 um 10:14 Uhr)
https://www.science.org/doi/10.1126/sciimmunol.abl5344
High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells (Hinzugefügt: 11.01.2022 um 10:12 Uhr)
https://www.science.org/doi/10.1126/sciimmunol.abl5652
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals (Hinzugefügt: 10.01.2022 um 12:17 Uhr)
https://www.medrxiv.org/content/10.1101/2022.01.04.21268586v1
Was ist T Zell Immunität? Pathophysiologie / Messung / Rolle Omikron (Hinzugefügt: 10.01.2022 um 11:55 Uhr)
https://www.youtube.com/watch?v=VIQTLSisGvQ
EUROIMMUN bringt SARS-CoV-2-Testsystem zur Bestimmung der T-Zell-Reaktion auf den Markt (Hinzugefügt: 30.12.2021 um 11:55 Uhr)
https://www.euroimmunblog.de/euroimmun-sars-cov-2-test-zur-bestimmung-der-t-zell-reaktion/
T-Zell-Immunität auf SARS-CoV-2 und deren Nachweismöglichkeiten – der aktuelle Wissensstand (Hinzugefügt: 30.12.2021 um 11:50 Uhr)
http://www.imd-berlin.de/fileadmin/user_upload/login/downloads/T_cell_response_to_SARS_COV_2_print.pdf
Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response (Hinzugefügt: 30.12.2021 um 11:43 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.28.474325v1
SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron (Hinzugefügt: 30.12.2021 um 11:35 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.26.21268380v1
Complement activation induces excessive T cell cytotoxicity in severe COVID-19 (Hinzugefügt: 29.12.2021 um 17:43 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)01562-2?rss=yes&utm_source=dlvr.it&utm_medium=twitter
SARS-CoV-2-specific T cells in infection and vaccination (Hinzugefügt: 29.12.2021 um 16:11 Uhr)
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8408362/
Complement activation induces excessive T cell cytotoxicity in severe COVID-19 (Hinzugefügt: 28.12.2021 um 14:23 Uhr)
https://www.cell.com/cell/pdf/S0092-8674(21)01562-2.pdf?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867421015622%3Fshowall%3Dtrue
High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells (Hinzugefügt: 21.12.2021 um 12:48 Uhr)
https://www.science.org/doi/10.1126/sciimmunol.abl5652
Distinguishing COVID-19 infection and vaccination history by T cell reactivity (Hinzugefügt: 20.12.2021 um 16:37 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.15.472874v1
Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study (Hinzugefügt: 18.12.2021 um 15:01 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab954/6430423
Preliminary experimental data on T cell cross-reactivity to Omicron (Hinzugefügt: 17.12.2021 um 12:20 Uhr)
https://cdn.who.int/media/docs/default-source/blue-print/wendy-burgers_c19_whoconsulation_15dec2021.pdf?sfvrsn=2a2a7479_7
The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders (Hinzugefügt: 13.12.2021 um 11:18 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.08.21267444v1
T cells step up after SARS-CoV-2 vaccination with B cell depletion (Hinzugefügt: 06.12.2021 um 13:44 Uhr)
https://www.nature.com/articles/s41582-021-00582-w
Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques (Hinzugefügt: 04.12.2021 um 18:55 Uhr)
https://journals.asm.org/doi/epub/10.1128/mBio.01503-21
Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques (Hinzugefügt: 04.12.2021 um 18:55 Uhr)
https://journals.asm.org/doi/epub/10.1128/mBio.01503-21
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity (Hinzugefügt: 28.11.2021 um 15:28 Uhr)
https://www.nature.com/articles/s41586-021-04232-5
SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments (Hinzugefügt: 20.11.2021 um 11:03 Uhr)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2786409
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 (Hinzugefügt: 19.11.2021 um 20:23 Uhr)
https://www.nature.com/articles/s41586-021-04186-8
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study (Hinzugefügt: 19.11.2021 um 20:17 Uhr)
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00275-5/fulltext
How do people resist COVID infections? Hospital workers offer a hint (Hinzugefügt: 19.11.2021 um 15:46 Uhr)
https://www.nature.com/articles/d41586-021-03110-4?utm_source=twt_nat&utm_medium=social&utm_campaign=nature
Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 (Hinzugefügt: 19.11.2021 um 15:41 Uhr)
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7437499/
BNT162b2 vaccination induces durable SARS-CoV-2 specific T cells with a stem cell memory phenotype (Hinzugefügt: 14.11.2021 um 14:54 Uhr)
https://www.science.org/doi/10.1126/sciimmunol.abl5344
The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination (Hinzugefügt: 04.11.2021 um 09:09 Uhr)
https://www.sciencedirect.com/science/article/pii/S2772613421000068
The impact of viral mutations on recognition by SARS-CoV-2 specific T-cells (Hinzugefügt: 04.11.2021 um 08:28 Uhr)
https://www.cell.com/iscience/fulltext/S2589-0042(21)01322-5
Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques (Hinzugefügt: 24.08.2021 um 17:19 Uhr)
https://journals.asm.org/doi/10.1128/mBio.01503-21
Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine (Hinzugefügt: 03.08.2021 um 10:23 Uhr)
https://www.nature.com/articles/s41586-021-03841-4
SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection (Hinzugefügt: 03.08.2021 um 10:13 Uhr)
https://www.nature.com/articles/s41467-021-24938-4
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines (Hinzugefügt: 03.08.2021 um 09:49 Uhr)
https://www.medrxiv.org/content/10.1101/2021.07.21.21260928v1
SARS-CoV-2-specific immune response in COVID-19 convalescent individuals (Hinzugefügt: 13.07.2021 um 06:55 Uhr)
https://www.nature.com/articles/s41392-021-00686-1
CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients (Hinzugefügt: 09.07.2021 um 19:17 Uhr)
https://immunology.sciencemag.org/content/6/61/eabg5669
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer (Hinzugefügt: 03.07.2021 um 17:55 Uhr)
https://www.nature.com/articles/s41591-021-01386-7
Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (Hinzugefügt: 03.07.2021 um 17:54 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00204-4
Rapid determination of the wide dynamic range of SARS-CoV-2 Spike T cell responses in whole blood of vaccinated and naturally infected (Hinzugefügt: 01.07.2021 um 08:47 Uhr)
https://www.biorxiv.org/content/10.1101/2021.06.29.450293v1
Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19 (Hinzugefügt: 30.06.2021 um 14:32 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00827-5
The polarity and specificity of SARS-CoV2 -specific T lymphocyte responses determine disease susceptibility (Hinzugefügt: 23.06.2021 um 18:06 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.18.21258477v1
High-affinity, neutralizing antibodies to SARS-CoV-2 can be made in the absence of T follicular helper cells (Hinzugefügt: 13.06.2021 um 16:28 Uhr)
https://www.biorxiv.org/content/10.1101/2021.06.10.447982v1
CD4+ T cell lymphopenia and dysfunction in severe COVID-19 disease is autocrine TNF-α/TNFRI-dependent (Hinzugefügt: 06.06.2021 um 14:38 Uhr)
https://www.biorxiv.org/content/10.1101/2021.06.02.446831v1
Landscape of epitopes targeted by T cells in 852 convalescent COVID-19 patients: Meta-analysis, immunoprevalence and web platform (Hinzugefügt: 27.05.2021 um 15:35 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00155-5
SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees (Hinzugefügt: 26.05.2021 um 08:47 Uhr)
https://immunology.sciencemag.org/content/6/59/eabj1750.full
SARS-CoV-2 Human T cell Epitopes: adaptive immune response against COVID-19. (Hinzugefügt: 25.05.2021 um 14:11 Uhr)
https://www.cell.com/action/showPdf?pii=S1931-3128%2821%2900238-9
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer (Hinzugefügt: 25.05.2021 um 14:03 Uhr)
https://www.nature.com/articles/s41591-021-01386-7.epdf?sharing_token=H0qcJ41HMWP0IKSTmhiWqdRgN0jAjWel9jnR3ZoTv0MXrr8TQM4wwmkmdHNMvaILwf2KR3oBX4OPSrUUYKBDDBxCGQAkUlRpysYHiyaGx72_zSZVo-LqsQsTcy3yIKDZ4km0J8OPo6virM--yKq1q-UNnA7kXr5-mvTCpRhSn34%3D
Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients (Hinzugefügt: 22.05.2021 um 18:06 Uhr)
https://cancerdiscovery.aacrjournals.org/content/early/2021/05/14/2159-8290.CD-21-0191.article-info
Short Telomeres and a T-Cell Shortfall in COVID-19: The Aging Effect (Hinzugefügt: 22.05.2021 um 17:14 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.19.21257474v1
Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. (Hinzugefügt: 20.05.2021 um 06:38 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(21)00216-8
Targeting prohibitins at the cell surface prevents Th17‐mediated autoimmunity (Hinzugefügt: 15.05.2021 um 10:14 Uhr)
https://www.embopress.org/doi/full/10.15252/embj.201899429
In fight against Covid variants some firms target T cell jabs (Hinzugefügt: 09.05.2021 um 14:15 Uhr)
https://www.france24.com/en/live-news/20210508-in-fight-against-covid-variants-some-firms-target-t-cell-jabs
Impaired T-cell and antibody immunity after COVID-19 infection in chronically immunosuppressed transplant recipients (Hinzugefügt: 06.05.2021 um 09:24 Uhr)
https://www.biorxiv.org/content/10.1101/2021.05.03.442371v1
SARS -CoV-2 T-cell immunity to variants of concern following vaccination (Hinzugefügt: 05.05.2021 um 08:15 Uhr)
https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose (Hinzugefügt: 05.05.2021 um 08:09 Uhr)
https://science.sciencemag.org/content/early/2021/04/29/science.abh1282
Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination (Hinzugefügt: 23.04.2021 um 12:19 Uhr)
https://www.biorxiv.org/content/10.1101/2021.04.21.440862v1
Discrete immune response signature to SARS-CoV-2 mRNA vaccination versus infection (Hinzugefügt: 22.04.2021 um 12:29 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.20.21255677v1
CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naïve precursor frequency and T cell receptor promiscuity (Hinzugefügt: 18.04.2021 um 17:11 Uhr)
https://www.sciencedirect.com/science/article/pii/S1074761321001710
Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection (Hinzugefügt: 18.04.2021 um 07:49 Uhr)
https://rupress.org/jem/article/218/5/e20202617/211835/Highly-functional-virus-specific-cellular-immune
Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients (Hinzugefügt: 18.04.2021 um 07:47 Uhr)
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00134-1/fulltext
CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naïve precursor frequency and T cell receptor promiscuity (Hinzugefügt: 17.04.2021 um 09:31 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(21)00171-0
Lessons learned: new insights on the role of cytokines in COVID-19 (Hinzugefügt: 16.04.2021 um 12:19 Uhr)
https://www.nature.com/articles/s41590-021-00901-9
https://immunology.sciencemag.org/content/6/58/eabf7550.full (Hinzugefügt: 15.04.2021 um 06:12 Uhr)
https://immunology.sciencemag.org/content/6/58/eabf7550.full
Mucosal Associated Invariant T (MAIT) Cell Responses Differ by Sex in COVID-19 (Hinzugefügt: 15.04.2021 um 05:57 Uhr)
https://www.cell.com/med/fulltext/S2666-6340(21)00157-4
Covid-Immunität dürfte mit Botenstoff zusammenhängen (Hinzugefügt: 10.04.2021 um 12:12 Uhr)
https://www.derstandard.de/story/2000125714664/covid-immunitaet-duerfte-mit-botenstoff-zusammenhaengen
IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals (Hinzugefügt: 10.04.2021 um 12:12 Uhr)
https://www.nature.com/articles/s41467-021-22449-w
Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset (Hinzugefügt: 10.04.2021 um 06:08 Uhr)
https://www.cell.com/med/fulltext/S2666-6340(21)00152-5
Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses (Hinzugefügt: 10.04.2021 um 05:54 Uhr)
https://www.jci.org/articles/view/146922#.YHCx8ey7Z-s.reddit
Single Prime hAd5 Spike (S) + Nucleocapsid (N) Dual Antigen Vaccination of Healthy Volunteers Induces a Ten-Fold Increase in Mean S- and N- T-Cell Responses Equivalent to T-Cell Responses from Patients Previously Infected with SARS-CoV-2 (Hinzugefügt: 08.04.2021 um 06:29 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.05.21254940v1
SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63 (Hinzugefügt: 07.04.2021 um 17:28 Uhr)
https://www.jci.org/articles/view/149335
T-cell responses as a correlate of COVID-19 vaccination. A pilot study in Health Care Workers. (Hinzugefügt: 06.04.2021 um 07:29 Uhr)
https://www.medrxiv.org/content/10.1101/2021.03.31.21254472v1
Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees (Hinzugefügt: 01.04.2021 um 19:02 Uhr)
https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1
Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection (Hinzugefügt: 01.04.2021 um 18:56 Uhr)
https://www.nature.com/articles/s41467-021-22036-z
T Cells Recognize Recent SARS-CoV-2 Variants (Hinzugefügt: 01.04.2021 um 05:47 Uhr)
https://www.niaid.nih.gov/news-events/t-cells-recognize-recent-sars-cov-2-variants
Alterations in T and B cell function persist in convalescent COVID-19 patients (Hinzugefügt: 01.04.2021 um 05:45 Uhr)
https://www.cell.com/med/fulltext/S2666-6340(21)00115-X
T cells induced by COVID-19 infection respond to new virus variants -U.S. study (Hinzugefügt: 01.04.2021 um 05:33 Uhr)
https://www.reuters.com/article/us-health-coronavirus-variants-idUSKBN2BM3BZ
How to Train Your Dragon: Harnessing Gamma Delta T Cells Antiviral Functions and Trained Immunity in a Pandemic Era (Hinzugefügt: 29.03.2021 um 06:56 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2021.666983/full
Age-Related Dynamics of Lung-Resident Memory CD8+ T Cells in the Age of COVID-19 (Hinzugefügt: 29.03.2021 um 06:56 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2021.636118/full
Monozygotic twins discordant for severe clinical recurrence of COVID-19 show drastically distinct T cell responses to SARS-Cov-2 (Hinzugefügt: 29.03.2021 um 06:37 Uhr)
https://www.medrxiv.org/content/10.1101/2021.03.26.21253645v1
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals (Hinzugefügt: 25.03.2021 um 06:58 Uhr)
https://www.biorxiv.org/content/10.1101/2021.03.22.436441v1
T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity (Hinzugefügt: 23.03.2021 um 04:14 Uhr)
https://www.medrxiv.org/content/10.1101/2021.03.19.21251426v1
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals (Hinzugefügt: 19.03.2021 um 10:51 Uhr)
https://stm.sciencemag.org/content/early/2021/03/12/scitranslmed.abf7517
COVID-19 hospitalization rates rise exponentially with age, inversely proportional to thymic T-cell production (Hinzugefügt: 18.03.2021 um 21:48 Uhr)
https://royalsocietypublishing.org/doi/10.1098/rsif.2020.0982
Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-COV-2 (Hinzugefügt: 17.03.2021 um 01:49 Uhr)
https://www.cell.com/iscience/fulltext/S2589-0042(21)00279-0
New SARS-CoV-2 lineages could evade CD8+ T-cells response (Hinzugefügt: 14.03.2021 um 06:07 Uhr)
https://www.biorxiv.org/content/10.1101/2021.03.09.434584v1
Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection (Hinzugefügt: 12.03.2021 um 18:15 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2021.636768/full
Prolonged SARS-CoV-2 Infection in a CAR T-Cell Therapy Recipient (Hinzugefügt: 11.03.2021 um 08:19 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2777220
SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses (Hinzugefügt: 10.03.2021 um 08:20 Uhr)
https://immunology.sciencemag.org/content/6/57/eabg6461.full
Strong T-cell immune response specific to virus can prevent severe Covid-19: Study (Hinzugefügt: 10.03.2021 um 08:09 Uhr)
https://www.straitstimes.com/singapore/strong-t-cell-immune-response-specific-to-virus-can-prevent-severe-covid-19-studies-show
SARS-CoV-2 nutzt Verteidigungsmechanismus des Immunsystems zur Vermehrung (Hinzugefügt: 10.03.2021 um 08:07 Uhr)
https://www.aerzteblatt.de/nachrichten/121832/SARS-CoV-2-nutzt-Verteidigungsmechanismus-des-Immunsystems-zur-Vermehrung

Mehr zum Thema "7a allg. zu Impfungen/ vaccinations"

TZellfunktionen 10. März 2021 09:07 Bharat Biotech BBV154 (ChAd-SARS-CoV-2-S) 22. Januar 2021 10:21 Bharat Biotech BBV 152 Covaxin 3. Januar 2021 10:43 Novavax/ Sanofi 12. Dezember 2020 09:49 CanSino 22. Dezember 2020 14:09 CoVac1 (Tübingen) 25. Mai 2021 16:28 Mambisa 30. April 2022 13:15 Medicago 10. Mai 2022 10:25 Corbevax 7. Juni 2021 10:03 Sinopharm 10. Dezember 2020 10:55 Sinovac/ CoronaVac 31. Dezember 2020 12:30 Neutralisationstest 25. Februar 2021 19:55 BZellfunktion 17. März 2021 02:55 Oravax 24. Juli 2021 17:32 Antikörpertests/ antibody test 25. Oktober 2020 23:14 Zydus Cadila 17. Mai 2021 11:52 Butanvac 28. März 2021 11:04 Emergex 13. Dezember 2021 11:43 SKYCovione GSK 17. März 2021 03:20 Sputnik V 10. Dezember 2020 10:56 CureVac 14. Dezember 2020 19:38 Auffrischimpfungen/ Booster Shots 10. Mai 2021 08:02 Impfpass/ vaccine passport 3. März 2021 09:16 heterologes Impfschema (z.B. erst Astra Zeneca, dann mRNA)/ heterologous vaccination 5. Mai 2021 12:45 Verhalten nach Impfung/ behavior after vaccination 20. Februar 2021 13:22 Impfung nach Infektion 4. März 2021 09:00 Schwangerschaft/ pregnancy 17. April 2021 12:16 Durchbruchinfektionen/ breakthrough infections 18. April 2021 19:06 Impfnebenwirkungen allg. 31. Januar 2021 15:48 Thrombozytopenie nach mRNA Impfung 25. April 2021 23:24 bei Impfung beachten 12. März 2021 07:00 Immunsuppression und Impferfolg 6. April 2021 09:20 MS und Impfung 6. April 2021 09:12 andere Impfungen als gg. SARS-Cov-2/ other vaccinations 25. Oktober 2020 23:03 Schwangerschaft/ pregnancy 22. April 2021 14:24 Vektorimpfstoffe 8. März 2021 10:23 mRNA Impfungen/ mRNA vaccines 18. Dezember 2020 22:12 Mutationen/ variants of concern 1. Februar 2021 09:31 Herdenimmunität durch Impfung?/ herd immunity after vaccination 5. November 2020 08:03 Kinder/ children 26. Mai 2021 10:46 Impftermin erhalten 26. Januar 2021 09:56 Wer wird geimpft?/ who gets the vaccine 10. November 2020 08:31 Impfung gegen SARS-CoV-2/ vaccination against SARS-CoV-2 25. Oktober 2020 23:01 Impfschutz überprüfen 7. Juli 2021 09:02 Wirksamkeit im Vergleich 20. Oktober 2021 16:15

Weitere Themen

SARS-CoV-2 Pandemie Virus SARS-Cov-2 Masken/ masks Luftreiniger Risikoreduktion Impfungen Wuhan-type Originalvirus: in D in Vergangenheit verfügbare Impfstoffe gegen Originalvirus Impfungen BA.1: in D verfügbar gewesener angepasste Impfstoffe gegen Omicron BA.1 Impfung BA.2: Impfstoff gg BA.2 Impfung BA.4/5: in D in 2022/23 verfügbar gewesene Impfstoffe gegen BA.4/5 Impfung XBB: in D in 2023/24 verfügbar gewesene XBB- Booster Impfung JN.1/ KP.2: Herbst 2024 in D verfügbare Impfstoffe PrEP Tests Erkrankung - Symptome Covid-19 Risikopatienten Frühtherapie Behandlung monoklonale Antikörper 14y evtl. wirksame Behandlung 14z nicht empfohlene Behandlung 15 Long- Covid/ Post- Covid 16 Rechtliches/ legal information 17 Meine persönliche Vorgehensweise/ My personal approach 18 NICHT SARS-CoV-2 Übertragung Übertragungssituationen 2c Reisen/ travelling 3 NPIs 7y Immunität nach Infektion/ immunity after infection 0 alt Corona- Pandemie 10 Was tun wenn infiziert?/ To do when tested positive? 7a allg. zu Impfungen/ vaccinations

« Zurück zur Übersicht